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Objectives: Lung cancer is one of the most common causes of cancer-related 
deaths world-wide. Afatinib is an irreversible ErbB family blocker showing superior 
efficacy in EGFRm+ NSCLC as 1st-line treatment compared to standard-of-care 
chemotherapy. To date, no head-to-head trial results exist to compare afatinib, gefi-
tinib or erlotinib. Previous NMAs have compared the three treatments on an ITT 
level, but not by mutation type. This analysis attempts to fill this gap. MethOds: 
Based on the EGFRm+ study network requested by NICE a Bayesian approach NMA 
was conducted to estimate relative treatment effects of afatinib versus erlotinib and 
gefitinib for progression free survival (PFS) and overall survival (OS) per mutation 
type (common mutations: Del19 and L858R). Results: 9 studies were included, 
8 reported PFS and 5 OS by mutation type, respectively. Results from fixed effects 
models are reported. Afatinib significantly improved PFS in common mutations 
versus gefitinib (HR 0.43: CrI 0.24; 0.75) and erlotinib (HR 0.60; CrI 0.39; 0.91). Results 
also favored afatinib for both EGFR mutation subgroups Del19 and L858R, but did 
not reach statistical significance. Afatinib showed a high probability (> 80%) of being 
the best treatment both for common mutations and per mutation type. For OS, a 
trend favoring afatinib was shown in particular for Del19. The probability of afatinib 
being best for Del19 was > 70%. For L858R no difference in OS was detected between 
the TKIs. cOnclusiOns: In line with findings from previous NMAs, this analysis 
by mutation type confirms both for PFS and OS a consistent trend towards supe-
riority of afatinib versus reversible TKIs. Afatinib appears to be the best treatment 
option for patients with common mutations, in particular Del19 mutations. A direct 
trial-based comparison of the efficacy of these agents is warranted to clarify their 
relative benefits.
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Objectives: This analysis described health care costs over time—excluding ipili-
mumab drug costs—stratified by survival duration and baseline ECOG status, in 
patients receiving ipilimumab for advanced melanoma in the US community set-
ting. MethOds: We analyzed data from a retrospective chart review of patients 
with unresectable stage III/IV melanoma treated with ipilimumab as first-line 
monotherapy between 04/2011 and 09/2012. Hospitalizations, emergency depart-
ment visits, subsequent chemotherapy, radiation, surgeries, nursing home, and 
hospice visits costs were estimated using published sources and tariffs. Total costs, 
excluding ipilimumab drug costs, were calculated for 3 periods: treatment regimen 
(between first and last ipilimumab doses); post-regimen; and pre-death (within 90 
days of death). Monthly costs were compared for the total population and stratified 
by baseline ECOG status (0 vs. ≥ 1, when available) and survival (< 1 year vs. ≥ 1 year) 
using Wilcoxon rank sum tests. Results: Data were abstracted from 273 patient 
charts at 34 sites. Excluding ipilimumab drug costs, total monthly costs during the 
treatment regimen, post-regimen, and pre-death periods were $690, $2151, and 
$5123, respectively. Total monthly costs across all study periods were higher for 
patients with ECOG ≥ 1 (n= 135) vs. ECOG= 0 (n= 104) (p= 0.0294), particularly in the 
pre-death period ($5987 vs. $3460, respectively; p= 0.0143). A similar pattern was 
observed for patients surviving < 1 year (n= 109) vs. ≥ 1 year (n= 122) (p< 0.0001), with 
a difference of $9524 vs. $2955 (p< 0.0001) during the pre-death period (42 patients 
still alive after < 1 year follow-up were excluded from this analysis). Key cost drivers 
were hospitalizations (32.4% of total costs), followed by non-ipilimumab chemother-
apy (23.1%), hospice care (19.1%), and nursing home stays (12.5%). cOnclusiOns: 
In this population, monthly costs were significantly lower during the treatment 
regimen period than in subsequent periods. Survival ≥ 1 year and baseline ECOG= 0 
were associated with significantly lower total monthly costs, particularly in the 
pre-death period.
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Objectives: No standard of care exists for patients with relapsed or refractory 
mantle cell lymphoma (MCL) and treatment options are limited. This study sought 
to synthesize the clinical evidence of current treatments for relapsed or refractory 
MCL, its limitations, and discuss the implications for decision making. MethOds: 
A systematic literature review was conducted in MEDLINE of phase II, III, or IV 
clinical trials published in English between January 1, 2001 and May 2, 2013. 
Supplemental searches included EHA, AACR, ASCO, and ASH 2011–2013 confer-
ence proceedings. Results: Results of the review indicate a paucity of evidence 
relevant for decision making. Of 808 records reviewed, 17 trials in the R/R MCL 
population were identified, only three of which were randomized controlled trials; 
all others were single-arm trials. For most treatments, only one trial was available. 
These factors made it infeasible to conduct a meta-analysis or indirect comparison. 
Furthermore, there was a large amount of heterogeneity in the patient popula-
tions, trial designs, and reported outcomes, making it difficult to compare outcomes 
across trials. Finally, of the 17 trials identified, five reported progression-free sur-
vival (PFS) Kaplan–Meier (K-M) graphs and only three reported overall survival (OS) 
of ibrutinib to available treatments for R/R MCL patients. MethOds: A systematic 
literature review was conducted to identify clinical trials containing treatments of 
R/R MCL. Matching adjusted indirect comparison (MAIC), described by Signorovitch 
et al 2012, was utilized to obtain indirect relative treatment effect for ibrutinib 
compared to other treatments. Using individual patient level data (IPD), baseline 
characteristics of the ibrutinib trial patients were matched with the patients in the 
published studies to obtain overall response (ORR) and complete response (CR) rates 
based on balanced population between the ibrutinib and published studies. Kaplan 
Meir curves for overall survival and PFS of comparators were plotted alongside those 
of the matched ibrutinib patients. Results: Nineteen studies evaluating various 
treatments were identified. Five trials evaluating bortezomib, BR (bendamustine, 
rituximab), FCM (fludarabine, cyclophosphamide, mitoxantrone), FCM-R (fludara-
bine, cyclophosphamide, mitoxantrone, rituximab), and rituximab-hyper-CVAD 
were considered for matching. Complete matching of the IPD was possible for the 
bortezomib, FCM and FCM-R studies. Ibrutinib showed statistically significant bet-
ter odds of achieving ORR compared to bortezomib (OR 3.62; 95% CI 1.18-11.14) and 
FCM (OR 3.22; 95% CI 1.01-10.26). cOnclusiOns: The indirect analysis suggests a 
potential for improved ORR compared to a few relevant treatments in patients with 
R/R MCL. Phase III comparative confirmatory data with ibrutinib are anticipated 
in late 2014.
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Objectives: The NSABP/NCCTG trial (Romond et al. NEJM 2005; 353: 1673-1684) 
established the efficacy of trastuzumab in the adjuvant treatment of HER2+ early 
stage breast cancer (HER2+BC). Yet, little is known about the patterns of use and 
outcomes of adjuvant trastuzumab in clinical practice. The study aimed to esti-
mate the overall survival (OS) and relapse-free survival (RFS) of HER2+BC patients 
treated with adjuvant trastuzumab in the US Department of Defense (DOD) prac-
tice setting. MethOds: Adult women initiating adjuvant trastuzumab within 1 
year of BC surgery were identified in the DOD health claims database (01/2003-
12/2012). An algorithm based on secondary neoplasm ICD9 codes and treatment 
gaps and initiations was used to identify relapses. OS and RFS unadjusted rates 
at 3 and 4 years after the initiation of the adjuvant trastuzumab treatment were 
estimated from Kaplan-Meier plots. Results: The study sample included 3,188 
women (median age 63 years), followed for a median of 3.3 years after the initia-
tion of trastuzumab and treated continuously with trastuzumab for a median of 
12 months. Of these 3,188 women, 13.8% received neo-adjuvant therapy prior to 
the surgery, 17.7% relapsed, and 7.9% died during the follow-up. The OS rates at 3 
and 4 years were 93.2% (95% CI 92.1%-94.2%) and 90.0% (88.6%-91.2%), respectively. 
The corresponding RFS rates were 78.8% (77.1%-80.3%) and 75.8% (74.0%-77.5%), 
respectively. cOnclusiOns: The findings suggest that most HER2+BC patients in 
the DOD practice setting received per-label trastuzumab treatment (for 52 weeks) 
and had OS rates that are similar to the OS rates that were previously observed 
in the NSABP/NCCTG clinical trial (90.0% vs. 93% at four years). The lower RFS 
rates observed in this study versus the NSABP/NCCTG trial (75.8% vs. 85.7% at 
4 years), may be partially explained by differences in the characteristics of the 
patients, including age.
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Objectives: To assess the relative efficacy of first-line treatments in chronic mye-
loid leukaemia (CML), an updated systematic literature review (SLR) and indirect 
comparison (IC) were conducted with follow-up period up to 48 months. MethOds: 
We updated a SLR initially conducted in 2011. Medical databases were interrogated 
systematically in January 2014 to identify trials comparing first-line treatments for 
CML. Using a fixed-effect Bayesian model implemented in WinBUGS, ICs were made 
to calculate relative efficacy (cumulative complete cytogenetic response (CCyR) and 
major molecular response (MMR)) for dasatinib, nilotinib and imatinib. Results: 
Nineteen randomised controlled trials (RCTs) were included in the SLR, 10 were 
eligible for inclusion in the IC. Compared with imatinib 400mg by 12 months, odds 
of cumulative CCyR were significantly greater for dasatinib 100mg [odds ratio (OR) 
2.25,95% credible interval (CrI) 1.55-3.15], nilotinib 600mg [OR 2.23 (95% CrI 1.50-
3.21)] and 800mg [OR 1.94 (95% CrI 1.31-2.78)]. By 24 months compared with imatinib 
400mg, the odds remained significantly higher with nilotinib 600mg [OR 2.03 (95% 
CrI 1.28-3.10)] and 800mg [OR 1.70 (95% CrI 1.08-2.55)] and higher, but not signifi-
cant with dasatinib 100mg [OR 1.41 (95% CrI 0.85-2.22)]. By 12,24,36 and 48 months 
respectively, compared with imatinib 400mg, the odds of a MMR were: dasatinib 
100mg [OR 2.22 (95% CrI 1.52-3.15) / 2.09 (1.45-2.93) / 1.76 (1.22-2.48) / 1.90 (1.27-2.74)] 
nilotinib 600mg [OR 2.86 (95% CrI 1.95-4.08) / 3.24 (2.26-4.54) / 2.45 (1.70-3.43) / 2.54 
(1.75-3.59)] and 800mg [OR 2.76 (95% CrI 1.88-3.94) / 2.60 (1.82-3.62) / 2.12 (1.48-2.95)/ 
2.18 (1.51-3.06)]. For both outcomes at all time points, there was no significant differ-
ence between dasatinib and nilotinib. cOnclusiOns: Analysis including all avail-
able RCTs suggests that second-generation tyrosine kinase inhibitors dasatinib and 
nilotinib are more efficacious than imatinib 400mg and should be treatments of 
choice in newly diagnosed CML.
